| GTO ID | GTC2969 |
| Trial ID | NCT05292859 |
| Disease | Ovarian Cancer | Pancreatic Cancer | Cholangiocarcinoma | Lung Cancer | Colorectal Cancer |
| Altered gene | Neoantigen |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | Neoantigen TCR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Using the Sleeping Beauty System to Express T Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors |
| Year | 2022 |
| Country | United States |
| Company sponsor | Alaunos Therapeutics |
| Other ID(s) | TCR001-202 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||